Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen D Smith

Showing results (111-120 of 159) with videos related to

Pageof 16
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 12, 2021
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing AnalysisStephen D Smith, Paolo Lopedote, Yazeed Samara, et al.
Blood Advances|June 17, 2025
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomasChristina Poh, Jenna M Voutsinas, Mazyar Shadman, et al.
Frontiers in Veterinary Science|January 5, 2024
Geo-temporal patterns to design cost-effective interventions for zoonotic diseases -the case of brucellosis in the country of GeorgiaAriel L Rivas, Stephen D Smith, V Basiladze, et al.
British Journal of Haematology|February 8, 2020
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapyStephen D Smith, Brian G Till, Mazyar S Shadman, et al.
Journal of Cellular and Molecular Medicine|December 1, 2022
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world studyLorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, et al.
Leukemia & Lymphoma|July 11, 2022
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphomaLorena Panaite, Qian Vicky Wu, Jenna Voutsinas, et al.
Blood Advances|November 17, 2022
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHLSolomon A Graf, Ryan C Lynch, Chaitra S Ujjani, et al.
British Journal of Haematology|January 1, 2019
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trialLihua E Budde, David Wu, Daniel B Martin, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 5, 2023
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-UpCarrie Ho, Ajay K Gopal, Brian G Till, et al.
British Journal of Haematology|September 11, 2025
Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemiaChristina Poh, Xueyan Chen, Jenna Voutsinas, et al.
Pageof 16

Showing results (111-120 of 159) with videos related to

Sort By:
Pageof 16
Clinical Lymphoma, Myeloma & Leukemia|January 12, 2021
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing AnalysisStephen D Smith, Paolo Lopedote, Yazeed Samara, et al.
Blood Advances|June 17, 2025
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomasChristina Poh, Jenna M Voutsinas, Mazyar Shadman, et al.
Frontiers in Veterinary Science|January 5, 2024
Geo-temporal patterns to design cost-effective interventions for zoonotic diseases -the case of brucellosis in the country of GeorgiaAriel L Rivas, Stephen D Smith, V Basiladze, et al.
British Journal of Haematology|February 8, 2020
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapyStephen D Smith, Brian G Till, Mazyar S Shadman, et al.
Journal of Cellular and Molecular Medicine|December 1, 2022
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world studyLorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, et al.
Leukemia & Lymphoma|July 11, 2022
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphomaLorena Panaite, Qian Vicky Wu, Jenna Voutsinas, et al.
Blood Advances|November 17, 2022
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHLSolomon A Graf, Ryan C Lynch, Chaitra S Ujjani, et al.
British Journal of Haematology|January 1, 2019
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trialLihua E Budde, David Wu, Daniel B Martin, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 5, 2023
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-UpCarrie Ho, Ajay K Gopal, Brian G Till, et al.
British Journal of Haematology|September 11, 2025
Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemiaChristina Poh, Xueyan Chen, Jenna Voutsinas, et al.
Pageof 16